Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 63 5 2025 12 12 294 300 Minoo Mohraz 1 Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran Seyed Ehsan Kazerooni Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Arash Seifi Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Seyed Ali Dehghan Manshadi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. Seyed Ahmad SeyedAlinaghi Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Sciences, Tehran, Iran. Fereshteh Shahmari Golestan Department of Nursing, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Samaneh Nikkhoo Department of Nursing, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Alireza Abdollahi Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Sirous Jafari Department of Infectious Diseases, Research Center for Antibiotic Stewardship and Antimicrobial Resistance, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. Mahdokht Hajrahimi Department of Pulmonary and Critical Care Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. 2025 03 21 2025 04 27 The novel coronavirus caused by SARS-CoV-2 is still a public health concern as it can have dire consequences. Anti-inflammatory drugs are promising. Therefore, this study aimed to determine the safety and effectiveness of the ENDOR oral combination drug in the treatment of patients with COVID-19. This double-blinded, randomized controlled trial was conducted at the Imam Khomeini Hospital complex in Tehran, Iran. All COVID-19 patients who were admitted to the Imam Khomeini hospital complex from April 2022 to April 2023 and who were 18-75-Year-Old signed the consent form to participate in this study, were not pregnant, and did not need mechanical ventilation at admission. In this study of 200 patients (50% in the Endor group and 50% in the placebo group), 56.8% were male, and the mean age was 65.02±14.94. There were no statistically significant differences observed between the Endor and control groups across time for temperature (P=.075), WBC (P=.095), CRP (P=.108), sodium (P=.323), or calcium (P=.352). The slope of the decrease in ESR and the body temperature, as well as the slope of the increase in oxygen saturation in the Endor group, was higher than in the control group. Statistically significant differences between the Endor and control groups over time for respiratory rate (P=.003), oxygen saturation (P<.001), and potassium (P=.031) were observed. The decreasing slope of the respiratory rate in the Endor group was significantly higher than in the control group. ENDOR with anti-inflammatory features helps COVID-19 hospitalized patients recover faster by improving oxygen saturation, lowering fever, and decreasing respiratory rate. https://acta.tums.ac.ir/index.php/acta/article/view/11603 https://acta.tums.ac.ir/index.php/acta/article/download/11603/5984